A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11145 participants.

Also called NCT01156571

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 11,145 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01156571
Other papers using this trial's data
  • Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial International journal of cardiology, 2019-03-01 DOI, PubMed 30563770
  • Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) Circulation, 2016-09-06 DOI, PubMed 27482008, PMC5006794 In the PMC Open Access subset under CC BY.
  • Effect of platelet inhibition with cangrelor during PCI on ischemic events The New England journal of medicine, 2013-04-04 DOI, PubMed 23473369
  • Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial JACC. Cardiovascular interventions, 2016-09-26 DOI, PubMed 27659566
  • Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial Circulation, 2016-01-19 DOI, PubMed 26762525, PMC4894784 In the PMC Open Access subset under CC BY.
  • Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention) Journal of the American College of Cardiology, 2014-02-25 DOI, PubMed 24184169
  • Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial European heart journal, 2018-12-07 DOI, PubMed 30203006, PMC6284164 PubMed links an erratum for this paper. Erratum: PMID 30753500 In the PMC Open Access subset under CC BY-NC.
  • Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX Circulation. Cardiovascular interventions, 2022-01 DOI, PubMed 34915723, PMC8765214 In the PMC Open Access subset under CC BY-NC-ND.
  • The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX European heart journal, 2016-04-07 DOI, PubMed 26400827, PMC4823635 In the PMC Open Access subset under CC BY.
  • Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial Circulation. Cardiovascular interventions, 2016-06 DOI, PubMed 27313282, PMC4920208 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01156571. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2013-06-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
Acronym
CHAMPION
Condition
Atherosclerosis
Condition
Acute Coronary Syndrome
Intervention (Drug)
cangrelor P2Y12 (platelet) inhibitor
Intervention (Drug)
Clopidogrel - 300 or 600 mg (study arm)
Intervention (Drug)
Clopidogrel 600 mg post cangrelor
Lead sponsor
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct01156571
Content hash
b557b285187692a2acb390efc06c29941c339afefe2f7435d4b36dab04b05976